Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8910211 | 0.88 | SLC6A2 (0.45) | TAAR1SLC6A2LMNACYP2D6MAOB | |
| SCHEMBL27999855 | 0.84 | SLC6A2 (0.58) | TAAR1SLC6A2LMNACYP2D6TRPA1 | |
| SCHEMBL3461930 | 0.80 | ALDH1A1 (0.44) | TAAR1SLC6A2LMNACYP2D6MAOB | |
| SCHEMBL27477280 | 0.78 | ALDH1A1 (0.42) | TAAR1SLC6A2LMNACYP2D6MAOB | |
| SCHEMBL11224549 | 0.78 | TDP1 (0.50) | TAAR1SLC6A2LMNACYP2D6MAOB | |
| SCHEMBL5783370 | 0.77 | TDP1 (0.44) | TAAR1SLC6A2LMNAALDH1A1HPGD | |
| SCHEMBL27479368 | 0.75 | DRD2 (0.41) | TAAR1SLC6A2ALDH1A1HPGDALOX15 | |
| SCHEMBL315316 | 0.75 | ALDH1A1 (0.48) | TAAR1SLC6A2LMNACYP2D6MAOB | |
| SCHEMBL2313943 | 0.75 | SLC6A2 (0.58) | TAAR1SLC6A2LMNACYP2D6TRPA1 | |
| SCHEMBL11066485 | 0.74 | TP53 (0.44) | TAAR1SLC6A2LMNACYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE HOLDINGS CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9801877-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2017-02-09 | — | — | US | disclosed |
| EP-3020402-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Holdings Corporation (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-1622569-B1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | INCYTE CORP (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | disclosed |
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| US-8637497-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2617419-A1 | Aza spiro alkane derivatives as inhibitors of metallproteases | Incyte Corporation (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7723349-B2 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090124649-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1622569-A4 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | INCYTE CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1678167-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Incyte Corporation (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1622569-A2 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Corporation (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005037826-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION | 2004-12-23 | — | — | US | disclosed |
| WO-2004096139-A2 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | MMP9, MMP3, MMP12 | TAAR1 977/4885SLC6A2 3825/4885LMNA 2622/4885 |
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | TAAR1 977/4885SLC6A2 3825/4885LMNA 2622/4885 |
| US-20090124649-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | TAAR1 977/4885SLC6A2 3825/4885LMNA 2622/4885 |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | TAAR1 3673/4885SLC6A2 2462/4885LMNA 2198/4885 |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | MMP9, MMP25, HDAC5 | TAAR1 1551/4885SLC6A2 2572/4885LMNA 3144/4885 |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | TAAR1 977/4885SLC6A2 3825/4885LMNA 2622/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | TAAR1 3811/4885SLC6A2 2044/4885LMNA 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.